CAR-T细胞治疗中枢神经系统肿瘤的神经毒性综述
本文综述了CAR-T细胞治疗中枢神经系统肿瘤的临床前数据与早期临床试验,聚焦治疗相关神经毒性的特征、机制与管理。文章区分了ICANS(免疫效应细胞相关神经毒性综合征)、TIAN(肿瘤炎症相关神经毒性)及其他非ICANS神经毒性,指出TIAN在局部CAR-T试验中常见且多可逆,而ICANS少见,强调鉴别二者对临床管理至关重要。
要点
- ICANS为全身细胞因子介导过程,TIAN为肿瘤局部炎症所致。
- TIAN在局部CAR-T治疗CNS肿瘤的I期试验中常见,多短暂可逆。
- 鉴别ICANS与TIAN对选择皮质类固醇、IL-1阻断或脑脊液分流至关重要。
核心结论
- CAR-T细胞治疗CNS肿瘤可诱导独特的神经毒性,反映脑内局部免疫激活。
- 区分ICANS与TIAN对适当管理至关重要。
- 标准化分级标准、前瞻性神经认知监测和合理CAR设计是安全推进神经肿瘤学CAR-T治疗的关键下一步。
研究设计与样本
- 综述临床前数据和早期临床试验,聚焦CNS肿瘤CAR-T治疗相关神经毒性的特征、机制和管理。
- 检查三大类神经毒性:ICANS、TIAN和其他非ICANS神经毒性(NINTs),包括运动和神经认知治疗中出现的事件。
主要发现
- ICANS反映全身细胞因子介导过程。
- TIAN代表肿瘤部位局部炎症,产生机械性(1型)或电生理性(2型)神经功能障碍。
- TIAN在CNS肿瘤局部CAR-T治疗的I期试验中常见,常短暂可逆,可能需要皮质类固醇、IL-1阻断或脑脊液分流。
- ICANS在此背景下仍不常见。
- 新数据显示小胶质细胞激活和神经认知效应与化疗相关认知障碍平行。
临床怎么用
- 临床应区分ICANS与TIAN以指导管理。
- TIAN可能需要皮质类固醇、IL-1阻断或脑脊液分流。
- 需标准化分级标准和前瞻性神经认知监测。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Chimeric antigen receptor (CAR) T cell therapy has revolutionized treatment for hematologic malignanciesand is now being applied to central nervous system (CNS) tumors. As experience grows, distinct neurotoxicities are emerging that differ from those observed in systemic CAR T cell therapy. Understanding these toxicities is critical for optimizing safety and advancing clinical translation. METHODS: We reviewed preclinical data and early-phase clinical trials of CAR T cell therapy for CNS tumors, focusing on the characterization, mechanisms, and management of treatment-associated neurotoxicity. Three major categories were examined: immune effector cell–associated neurotoxicity syndrome (ICANS), tumorinflammation–associated neurotoxicity (TIAN), and other non-ICANS neurotoxicities (NINTs), including movement and neurocognitive treatment-emergent events. RESULTS: ICANS reflects a global, cytokine-mediated process, whereas TIAN represents localized inflammation at the tumor site, producing either mechanical (type 1) or electrophysiologic (type 2) neurologic dysfunction. TIAN is common across phase I trials of locoregional CAR T cell therapy for CNS tumors, often transient and reversible, and may require corticosteroids, IL-1 blockade, or cerebrospinal fluid diversion. ICANS remains uncommon in this setting. Emerging data also suggest microglial activation and neurocognitive effects paralleling chemotherapy-related cognitive impairment. CONCLUSION: CAR T cell therapy for CNS tumors induces unique neurotoxicities reflecting local immune activation within the brain. Differentiating ICANS from TIAN is essential for appropriate management. Standardized grading criteria, prospective neurocognitive monitoring, and rational CAR design are critical next steps in safely advancing CAR T cell therapy in neuro-oncology.
引用
- Mahdi J, Gust JA, Vitanza NA, et al. Neurotoxicity in central nervous system tumors treated with CAR T cell therapy: a review. J Neurooncol. 2025. PMID: 41171480. doi:10.1007/s11060-025-05251-2
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。